US scientists have prepared zirconium phosphate nanoplatelets (ZrP NPs) as carriers for the anticancer drug doxorubicin (DOX). The platelets showed improved cellular uptake and cytotoxicity of DOX in metastatic breast cancer cells. They were non-toxic to both healthy and malignant human cells, while they could carry a high dosage of drug and release it over a prolonged period.
The team says that the nanoplatelets could be used as a theranostic for simultaneous treatment and imaging of cancer.
Zirconium phosphate nanoplatelets: A biocompatible nanomaterial for drug delivery to cancer
Vipin Saxena, Agustín Díaz, Abraham Clearfield, James D Batteas and Muhammad Delwar Hussain
DOI: 10.1039/C3NR34242E
